91, almost the H Half of the Maraviroc  UK-427857 participants had a mean follow-up of 10 years. The prevention effects of aspirin in the primary Rpr Were with their effects in environments with increased Hter Gef Endangerment by the results of six studies in patients with a history of myocardial infarction, nine studies of patients with a history of a comparison ” TIA or stroke, and a study in patients with m ig severe diabetic retinopathy. 10 The results of the Antithrombotic Trialists Collaboration meta-analysis of individual patients showed a 12% proportional reduction of the H FREQUENCY of serious vascular Ren events and a 18% proportional reduction in the incidence of major coronary events. Most receivers singer of aspirin was 23% reduction in t on t is not more harmful MI, there was no apparent reduction in kardiovaskul Ren’s death. aspirin was associated with a significant reduction of 10 % in non-h hemorrhagic stroke associated nonsignifi. aspirin had no effect on the significance of vascular cant amount Ren causes of death, and there was no evidence of a protective effect on two-thirds of Todesf ll coronary vascular disease, the sixth because of stroke or vascular rer other causes of death. aspirin had no significant effect on the mortality cant t or non-vascular re cause of death unknown, but increased ht of greater risk eren extracranial bleeding. Absolute Nutznie he have the aspirin under the concept of arterial occlusive disease, which is, of vascular Ren events other than h hemorrhagic stroke, or t dlichen extracranial bleeding together. Among those helped a small risk allocation to prevent aspirin occlusive vascular Ren events four to five years after 1000, what was there chiefl a decline of three major coronary events. Hei t the receiver singer of two other big s extracranial hemorrhages per 1000 over the same period was offset by 5 years, but there was no significant risk of substantial excess of h hemorrhagic stroke. Among the much smaller number of participants at moderate risk, the net effect of aspirin for 5 years disease vascular re events statistically uncertain, because despite a reduction defi ned in major coronary events, there was no significant reduction Mutma significant Lichen ish ischemic stroke, and there was a surplus of two hours haemorrhagic Schlaganf lle and heavy bleeding. About H half of the t dlichen h Schlaganf hemorrhagic cases were so this risk clearly outweigh the positive hearts of men with moderate risks. The results of three graduated subsequently end Prim rpr prevention studies involving 7.165 patients with diabetes, peripheral arterial occlusive disease, or both are compatible with those of the individual meta-analysis of individual patient by the Antithrombotic Trialists performed Collaboration. 93 95 A meta-analysis of all nine primary rpr prevention studies, a significant reduction of the deferred showed cant in mortality t all causes with aspirin, but no reduction in the kardiovaskul Ren mortality t, 96, fi nd raises the M possibility that aspirin also prevents non-vascular Ren mortality t. Previous meta-analyzes on the effects of therapy with platelet aggregation inhibitors in people at high risk of occlusive arterial disease 7 have research chemicals library shown that was the beneficiary of aspirin far outweigh the risk of bleeding. However, the majority of participants in the studies on the primary rpr prevention was low absolute risk of CHD in average, the j HAZARDOUS risk of stroke in studies on primary rpr Convention was only about.